Lipoic Acid

NutraPedia - Evidence-Based Supplement Research

Back to Table of Contents
Health Goals: detox inflammation energy

Research Overview

Across the abstracts, α‑lipoic acid (ALA; lipoic acid, LA) is most frequently studied in the context of oxidative stress biology and metabolic disease, particularly diabetes and its complications. Mechanistically oriented work emphasizes the ALA/dihydrolipoic acid (DHLA) redox couple as an amphiphilic antioxidant system capable of reactive oxygen species scavenging, transition-metal chelation, and regeneration of endogenous antioxidants (notably glutathione, and vitamins C and E), with downstream anti-inflammatory and neuroprotective implications. A second major research area concerns pharmacokinetics and formulation science: oral ALA has relatively low bioavailability (~30%) and a short half-life due to degradation and limited stability/solubility, motivating studies of improved delivery (e.g., liquid formulations, amphiphilic matrices, and nanoformulations) and comparisons of enantiomers, with the R-enantiomer generally showing more favorable pharmacokinetic parameters than the S form.

The strongest evidence described in these abstracts supports ALA as a clinically useful adjunct for diabetic neuropathy symptoms (pain/paresthesia) and, more broadly, as a modulator of redox imbalance in preclinical models of diabetes and cardiovascular-related oxidative stress. Multiple reviews converge on consistent biochemical plausibility (redox cycling, antioxidant network support, and metal chelation) and report “successful clinical studies” in diabetes-related complications, although the abstracts do not provide effect sizes or trial quality details. For burning mouth syndrome, evidence from randomized trials synthesized in a systematic review suggests the pooled short-term analgesic effect of ALA is low, with more favorable signals emerging over longer follow-up; however, other interventions (e.g., cognitive behavioral therapy, topical clonazepam/capsaicin, and laser therapy) appear to show more robust and consistent benefit in that literature.

Key gaps highlighted include the need for better-designed and larger clinical trials (multi-center, placebo-controlled, multi-arm, and with longitudinal follow-up) to establish standardized protocols and to clarify durability of benefit across indications beyond diabetic neuropathy. Additional research is needed to link improved formulations and enantiomer selection to clinically meaningful outcomes (not just higher plasma exposure), to characterize age-related determinants of bioavailability and response, and to more clearly define which patient subgroups benefit most. Finally, while broad potential applications are proposed (neurodegenerative, cardiovascular, anti-aging, fertility, and even infectious disease contexts), the abstracts collectively indicate that much of this remains driven by mechanistic and preclinical evidence, requiring more rigorous clinical validation and safety/interaction assessment in target populations.

1. What conditions has Lipoic Acid been studied for?

  • Diabetes-related complications, especially diabetic neuropathy / diabetic polyneuropathy (pain, paresthesia, neuropathic symptoms) and broader “complications of diabetes.”

  • Cardiovascular diseases and cardiometabolic risk contexts (mentioned as studied; evidence described as mixed/controversial in humans in one review).

  • Obesity / weight-loss and anthropometric outcomes (meta-analysis referenced; human results described as controversial in a clinical review).

  • Burning mouth syndrome (as an oral supplement category evaluated in randomized trials and pooled analyses).

  • Neurodegenerative disorders / neuroprotection (review-level discussion; largely preclinical/in vivo and mechanistic emphasis).

  • Inflammatory conditions and pain more broadly (review of oral supplementation across “pain” and “inflammatory diseases”).

  • Aging / endothelial dysfunction and age-related decline in endogenous ALA (review-level discussion; includes animal model longevity signals).

  • Cancer-related contexts (review-level discussion including cytotoxic/antiproliferative effects; largely preclinical and not established as clinical therapy in the abstracts provided).

  • Central nervous system-related diseases (mentioned in a pharmacokinetics/formulation review spanning preclinical to clinical trials).

  • Pregnancy-related abnormalities (mentioned as an area covered by a review; no specific outcomes provided in the abstracts shown).

  • COVID-19 (mentioned in a review as part of “most recent clinical data,” without specific trial outcomes in the abstract provided).

  • Infertility / PCOS (mentioned in a review; not supported with specific clinical trial outcomes in the abstract provided).

2. Does it work in treating those conditions? Summarize the evidence.

  • Diabetic neuropathy (painful DN): The strongest direct clinical signal in the provided abstracts. In an oral study using 600 mg/day for 40 days in patients with painful diabetic neuropathy, multiple symptom and quality-of-life scores (NSS, SPNSQ, DN4; BPI, NPSI, SDS) improved significantly from baseline, and 50% of patients rated their condition “much better” or “very much better.” Triglycerides decreased, while fasting glucose and most lipids did not change over 40 days.

    Limitations: The abstract does not describe a placebo control; duration was short (40 days). Reviews also note that ALA is “widely used” for diabetic polyneuropathy-associated pain/paresthesia, implying broader clinical experience, but the abstracts provided do not quantify effect sizes across multiple RCTs.

  • Burning mouth syndrome (BMS): A systematic review of randomized trials found the pooled effect of ALA on pain score improvement was low in the short term, but positive effects increased in long-term assessment (>3 months). The review also emphasized inconsistency and the need for larger, multicenter, longitudinal trials.

  • Obesity / weight loss: A meta-analysis of placebo-controlled trials is referenced, but the abstract excerpt is incomplete and does not provide the pooled results. Separately, a clinical review states that human findings in obesity are controversial.

  • Cardiovascular disease (CVD): Reviews describe ALA as tested in CVD and note mechanistic plausibility (redox modulation, anti-inflammatory effects), but one review explicitly states that human results in CVD are controversial. No specific clinical endpoints or effect sizes are provided in the abstracts shown.

  • Neurodegenerative disorders / neuroprotection: Multiple reviews argue ALA is a promising neuroprotective candidate based on antioxidant/anti-inflammatory/antiapoptotic properties and in vitro/in vivo findings. However, the abstracts provided do not present definitive human clinical outcomes showing slowed progression of neurodegenerative disease.

  • Other areas (cancer, infertility/PCOS, pregnancy abnormalities, COVID-19): Mentioned in review abstracts as potential or discussed applications, but no specific, reliable clinical efficacy conclusions can be drawn from the provided abstracts alone.

3. What health benefits does it have?

  • Antioxidant activity (“universal antioxidant”): Across multiple reviews, ALA (and its reduced form DHLA) is described as scavenging reactive oxygen species, acting in both aqueous and lipid environments (amphiphilic), and having a strong redox potential.

  • Recycling/boosting other antioxidants: The abstracts state ALA/DHLA can increase tissue levels of reduced forms of other antioxidants, including glutathione, and can help recycle vitamins C and E.

  • Metal chelation: Reviews describe ALA as able to chelate metals and “chelate toxic metals” directly and indirectly (including via enhancing intracellular glutathione).

  • Anti-inflammatory effects: One review notes anti-inflammatory action that can be independent of antioxidant activity; others describe anti-inflammatory effects as part of its pleiotropic profile.

  • Mitochondrial bioenergetics support: ALA is naturally located in mitochondria and functions as a cofactor for pyruvate dehydrogenase and α-ketoglutarate dehydrogenase complexes, linking it to energy metabolism.

  • Neuropathic symptom relief (most clinically grounded benefit in the provided abstracts): In painful diabetic neuropathy, oral ALA (600 mg/day) was associated with improved neuropathic symptom scores and improved quality-of-life measures over 40 days.

  • Pain/inflammation outcomes: A clinical review summarizing oral supplementation reports beneficial effects on inflammation and pain overall, though it notes mixed findings in CVD/obesity.

4. Does it have any downsides or side effects?

  • Pharmacokinetic limitations (a major practical downside): Multiple abstracts state ALA has low bioavailability (~30%) and a short half-life, attributed to hepatic degradation, reduced solubility, and instability in the stomach. This can limit therapeutic efficacy unless formulation is optimized.

  • Formulation-dependent absorption: Reviews note that liquid formulations may yield higher plasma concentrations than solid forms, and that innovative formulations (including amphiphilic matrices and nanoformulations) can improve absorption/bioavailability.

  • Age effects: One review states bioavailability may depend on age, while no gender difference was found (suggesting dosing/response may be less predictable across age groups).

  • Adverse effects: One abstract characterizes the ALA/DHLA system as having “no major adverse effects.” However, the provided abstracts do not list specific side effects or rates (e.g., gastrointestinal symptoms), and one review calls for more clinical trials to guide professionals regarding safety of prescription. Overall, based on these abstracts alone, safety appears generally favorable but incompletely characterized.

  • Clinical uncertainty in some indications: For CVD and obesity, human findings are described as controversial, which is a downside from an evidence/expectations standpoint (potential for limited benefit depending on the goal).

5. Is it beneficial or harmful for any genetic variations (pharmacogenomics)?

The provided abstracts do not report pharmacogenomic findings (no specific gene variants predicting response, adverse effects, or dosing needs).

  • Enantiomer-related differences (not genetics, but relevant to “who responds”): One review notes the R-enantiomer has better pharmacokinetic parameters and increased bioavailability compared with the S-enantiomer. This is a formulation/chemical form issue rather than a human genetic variant.

  • What cannot be concluded from these abstracts: Whether variants in antioxidant defense pathways, mitochondrial enzymes, hepatic metabolism/transporters, or diabetes-related genes modify ALA efficacy or risk is unknown based on the provided text.

References

  1. Alpha-Lipoic Acid: Biological Mechanisms and Health Benefits.
    Fabiana Superti, Rosario Russo (2024) - Antioxidants (Basel, Switzerland)
  2. Insights on the Use of α-Lipoic Acid for Therapeutic Purposes.
    Bahare Salehi, Yakup Berkay Yılmaz, Gizem Antika, Tugba Boyunegmez Tumer, Mohamad Fawzi Mahomoodally, Devina Lobine, Muhammad Akram, Muhammad Riaz, Esra Capanoglu, Farukh Sharopov, Natália Martins, William C Cho, Javad Sharifi-Rad (2019) - Biomolecules
  3. A systematic review of treatment for patients with burning mouth syndrome.
    Huann Lan Tan, Jared G Smith, Jan Hoffmann, Tara Renton (2022) - Cephalalgia : an international journal of headache
  4. Molecular and Therapeutic Insights of Alpha-Lipoic Acid as a Potential Molecule for Disease Prevention.
    Amit Kumar Tripathi, Anup Kumar Ray, Sunil Kumar Mishra, Siddharth Mall Bishen, Hirdyesh Mishra, Aman Khurana (2023) - Revista brasileira de farmacognosia : orgao oficial da Sociedade Brasileira de Farmacognosia
  5. Direct and indirect antioxidant properties of α-lipoic acid and therapeutic potential.
    Luc Rochette, Stéliana Ghibu, Carole Richard, Marianne Zeller, Yves Cottin, Catherine Vergely (2013) - Molecular nutrition & food research
  6. Biochemical and clinical relevance of alpha lipoic acid: antioxidant and anti-inflammatory activity, molecular pathways and therapeutic potential.
    Daniele Tibullo, Giovanni Li Volti, Cesarina Giallongo, Sonia Grasso, Daniele Tomassoni, Carmelina Daniela Anfuso, Gabriella Lupo, Francesco Amenta, Roberto Avola, Vincenzo Bramanti (2017) - Inflammation research : official journal of the European Histamine Research Society ... [et al.]
  7. Natural Molecules and Neuroprotection: Kynurenic Acid, Pantethine and α-Lipoic Acid.
    Fanni Tóth, Edina Katalin Cseh, László Vécsei (2021) - International journal of molecular sciences
  8. Lipoic Acid: its antioxidant and anti-inflammatory role and clinical applications.
    Fabiana Andréa Moura, Kívia Queiroz de Andrade, Juliana Célia Farias dos Santos, Marília Oliveira Fonseca Goulart (2015) - Current topics in medicinal chemistry
  9. Effect of α-lipoic acid on symptoms and quality of life in patients with painful diabetic neuropathy.
    Evangelos Agathos, Anastasios Tentolouris, Ioanna Eleftheriadou, Panagiota Katsaouni, Ioannis Nemtzas, Alexandra Petrou, Christina Papanikolaou, Nikolaos Tentolouris (2018) - The Journal of international medical research
  10. Alpha-lipoic acid supplement in obesity treatment: A systematic review and meta-analysis of clinical trials.
    Nazli Namazi, Bagher Larijani, Leila Azadbakht (2018) - Clinical nutrition (Edinburgh, Scotland)
  11. Potential for Novel Therapeutic Uses of Alpha Lipoic Acid.
    Babatunde Fasipe, Andre Faria, Ismail Laher (2023) - Current medicinal chemistry
  12. Antioxidants in the treatment of diabetes.
    Saeid Golbidi, S Alireza Ebadi, Ismail Laher (2011) - Current diabetes reviews
  13. α-Lipoic Acid, an Organosulfur Biomolecule a Novel Therapeutic Agent for Neurodegenerative Disorders: An Mechanistic Perspective.
    Heena Khan, Thakur Gurjeet Singh, Randhir Singh Dahiya, Mohamed M Abdel-Daim (2022) - Neurochemical research
  14. Mitochondrial Dysfunction and Alpha-Lipoic Acid: Beneficial or Harmful in Alzheimer's Disease?
    Sávio Monteiro Dos Santos, Camila Fernanda Rodrigues Romeiro, Caroline Azulay Rodrigues, Alícia Renata Lima Cerqueira, Marta Chagas Monteiro (2019) - Oxidative medicine and cellular longevity
  15. Nanotechnological Approaches to Enhance the Potential of α-Lipoic Acid for Application in the Clinic.
    Chiara Bellini, Fabrizio Mancin, Emanuele Papini, Regina Tavano (2024) - Antioxidants (Basel, Switzerland)
  16. The disulfide compound α-lipoic acid and its derivatives: A novel class of anticancer agents targeting mitochondria.
    Bastian Dörsam, Jörg Fahrer (2016) - Cancer letters
  17. Review of lipoic acid: From a clinical therapeutic agent to various emerging biomaterials.
    Shao-Yang Lv, Suisui He, Xiao-Li Ling, Yue-Qin Wang, Cong Huang, Jin-Rong Long, Jia-Qi Wang, Yang Qin, Hua Wei, Cui-Yun Yu (2022) - International journal of pharmaceutics
  18. Alpha-Lipoic Acid as an Antioxidant Strategy for Managing Neuropathic Pain.
    Max Denisson Maurício Viana, Pedro Santana Sales Lauria, Alyne Almeida de Lima, Luiza Carolina França Opretzka, Henrique Rodrigues Marcelino, Cristiane Flora Villarreal (2022) - Antioxidants (Basel, Switzerland)
  19. Protective effects of alpha lipoic acid (ALA) are mediated by hormetic mechanisms.
    Edward J Calabrese, Evgenios Agathokleous, Gaurav Dhawan, Rachna Kapoor, Vittorio Calabrese (2023) - Food and chemical toxicology : an international journal published for the British Industrial Biological Research Association
  20. Alpha-lipoic acid (ALA) supplementation effect on glycemic and inflammatory biomarkers: A Systematic Review and meta- analysis.
    Mehran Rahimlou, Maryam Asadi, Nasrin Banaei Jahromi, Anahita Mansoori (2019) - Clinical nutrition ESPEN


Want personalized supplement recommendations based on your genetics?
Upload Whole Genome Sequencing (WGS) raw DNA data today!
Or upload raw DNA data to get started with your free analysis!